BioVersys’ BV100 Phase 2 exploratory data selected for rapid fire and poster presentations at IDWeek 2026
With BV100 now recruiting patients in its Phase 3 registration trial, we remain focused on advancing BV100 as a potential…
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
